Evacetrapib Appears Futile in High-Risk Vascular Disease

Share this content:
Evacetrapib Appears Futile in High-Risk Vascular Disease
Evacetrapib Appears Futile in High-Risk Vascular Disease

WEDNESDAY, May 31, 2017 (HealthDay News) -- For patients with high-risk vascular disease, evacetrapib does not affect the primary efficacy end point of first occurrence of any component of a composite of death from cardiovascular causes, myocardial infarction, stroke, coronary revascularization, or hospitalization for unstable angina, according to a study published in the May 18 issue of the New England Journal of Medicine.

A. Michael Lincoff, M.D., from the Cleveland Clinic, and colleagues enrolled 12,092 patients with high-risk vascular disease. Participants were randomized to receive evacetrapib or matching placebo daily, as well as standard medical therapy.

The researchers observed a 31.1 percent decrease in the mean low-density lipoprotein cholesterol level with evacetrapib versus a 6.0 percent increase with placebo at three months; 133.2 and 1.6 percent increases were seen in the mean high-density lipoprotein cholesterol levels with evacetrapib and placebo, respectively. The trial was terminated early due to lack of efficacy after 1,363 of the planned 1,670 primary end-point events had occurred. A primary end point occurred in 12.9 and 12.8 percent of patients in the evacetrapib and placebo groups, respectively, after a median of 26 months (hazard ratio, 1.01; 95 percent confidence interval, 0.91 to 1.11; P = 0.91)

"Although the cholesteryl ester transfer protein inhibitor evacetrapib had favorable effects on established lipid biomarkers, treatment with evacetrapib did not result in a lower rate of cardiovascular events than placebo among patients with high-risk vascular disease," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Eli Lilly, which manufactures evacetrapib and funded the study.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

Mortality Estimates Favor Annual Mammography From Age 40

Mortality Estimates Favor Annual Mammography From Age 40

Researchers estimate thousands of U.S. lives would be saved each year if mammograms started at age 40

Anti-Vaccine Info in Pregnancy May Delay Infant Immunization

Anti-Vaccine Info in Pregnancy May Delay Infant Immunization

Even if pregnant women later hear better info from doctors, they may still wait on vaccines

Hours Worked Impacted by Kids for Female, Not Male Doctors

Hours Worked Impacted by Kids for Female, Not ...

Findings from a national sample of dual-physician couples

is free, fast, and customized just for you!

Already a member?

Sign In Now »